clinical trial · NCT04673266
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
Lymphoma PatientsThrombocytopeniaRomiplostim
brief summary
The purpose of this study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma. This study will also look at whether romiplostim can prevent the need for chemotherapy dose delays, chemotherapy dose reductions, and platelet transfusions. In addition, we will determine how safe it is to give romiplostim to people with lymphoma who have low platelet count from chemotherapy.
started
Dec 14, 2020
primary completion
Apr 7, 2026
completion
Apr 7, 2026
last updated
Apr 13, 2026
official title
Romiplostim for Prevention of Severe Chemotherapy Induced Thrombocytopenia in Lymphoma Patients - Phase II Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol